Skip to content
OpenCapital
Get started

MapLight Therapeutics, Inc. MPLT Q4 2025 Annual earnings

Reported May 14, 2026 · Before market open

Diluted EPS-$1.34Miss by $0.38
EPS estimate-$0.96

Next report

Aug 13, 2026 (in a month)
EPS estimate-$1.37

Financials

Q4 2025

Income statement

See full
Operating income-$83.4M-266%
Net income-$79.5M-275%

Balance sheet

See full
Cash & equivalents$46.7M+22.2%
Total debt$5.8M-11.8%
Total equity$458.4M+337%
Total assets$479.5M+250%

Cash flow

See full
Operating cash flow-$46.8M-118%
CapEx$376.0K+255%
Free cash flow-$47.2M-119%

Valuation & ratios

Valuation

as of 07/10/26
See full
Market cap$1.8B—
Enterprise value$1.75B—

Returns & leverage

See full
Debt / equity0×—
Current ratio20×+12.8×

Versus estimates

Diluted EPS

Q4 2025-$1.34Miss by $0.38
Q3 2025-$37.18Miss by $35.46

Ask the moment MapLight Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did MapLight Therapeutics, Inc. report Q4 2025 earnings?
MapLight Therapeutics, Inc. (MPLT) reported Q4 2025 earnings on May 14, 2026 before market open.
What were MapLight Therapeutics, Inc. 's Q4 2025 revenue and EPS?
MapLight Therapeutics, Inc. reported diluted EPS of $-1.34 for Q4 2025.
Did MapLight Therapeutics, Inc. beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.96 by $0.38.
Where can I find MapLight Therapeutics, Inc. 's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-224067) and the 10-K periodic report (0001193125-26-125072) directly on SEC EDGAR. The filing index links above go to sec.gov.